Yahoo
OTC Markets OTCQB - Delayed Quote USD

Northwest Biotherapeutics, Inc. (NWBO)

0.1700 0.0000 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for NWBO
  • Previous Close 0.1700
  • Open 0.1700
  • Bid 0.1690 x 3500000
  • Ask 0.1700 x 46000000
  • Day's Range 0.1660 - 0.1774
  • 52 Week Range 0.1400 - 0.3400
  • Volume 1,111,045
  • Avg. Volume 4,116,073
  • Market Cap (intraday) 289.958M
  • Beta (5Y Monthly) -0.61
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1.00

Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

www.nwbio.com

105

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NWBO
26.09%
S&P 500 (^GSPC)
10.73%

1-Year Return

NWBO
29.17%
S&P 500 (^GSPC)
11.11%

3-Year Return

NWBO
77.92%
S&P 500 (^GSPC)
81.91%

5-Year Return

NWBO
84.40%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY16
Revenue 71k
Earnings -30.71M
Profit Margin -43,249.30%

Q1

FY16

Q2

FY16

Q3

FY16

Q4

FY16

-30M
-20M
-10M
0
-40000.0%
-30000.0%
-20000.0%
-10000.0%

Analyst Insights

View More

Analyst Price Targets

1.00
1.00 Average
0.1700 Current
1.00 High

Latest Rating

Date 3/12/2014
Analyst Oppenheimer
Rating Action Downgrade
Rating Perform
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -59.64%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.17M

  • Net Income Avi to Common (ttm)

    -38.88M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    595k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -35.6M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: